Donaldson Capital Management LLC Buys 197,615 Shares of Pfizer Inc. (NYSE:PFE)

Donaldson Capital Management LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 21.3% during the first quarter, Holdings Channel reports. The firm owned 1,126,915 shares of the biopharmaceutical company’s stock after purchasing an additional 197,615 shares during the period. Pfizer makes up approximately 2.2% of Donaldson Capital Management LLC’s portfolio, making the stock its 18th largest position. Donaldson Capital Management LLC’s holdings in Pfizer were worth $40,828,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $2,219,532,000. Morgan Stanley increased its position in Pfizer by 16.4% in the fourth quarter. Morgan Stanley now owns 53,610,111 shares of the biopharmaceutical company’s stock worth $1,973,389,000 after buying an additional 7,540,245 shares during the last quarter. Bank of New York Mellon Corp increased its position in Pfizer by 12.1% in the fourth quarter. Bank of New York Mellon Corp now owns 64,756,839 shares of the biopharmaceutical company’s stock worth $2,383,700,000 after buying an additional 6,965,496 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Pfizer in the fourth quarter worth $162,707,000. Finally, Sanders Capital LLC increased its position in Pfizer by 10.6% in the fourth quarter. Sanders Capital LLC now owns 31,947,816 shares of the biopharmaceutical company’s stock worth $1,280,997,000 after buying an additional 3,051,838 shares during the last quarter. Institutional investors own 67.36% of the company’s stock.

NYSE:PFE opened at $40.02 on Monday. The firm has a market capitalization of $223.22 billion, a price-to-earnings ratio of 25.82, a P/E/G ratio of 2.79 and a beta of 0.70. Pfizer Inc. has a 52-week low of $31.61 and a 52-week high of $43.08. The stock has a fifty day moving average of $37.93 and a 200 day moving average of $36.89. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.13 and a current ratio of 1.40.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 4th. The biopharmaceutical company reported $0.93 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.78 by $0.15. The company had revenue of $14.58 billion during the quarter, compared to analyst estimates of $13.41 billion. Pfizer had a return on equity of 24.88% and a net margin of 17.85%. The firm’s quarterly revenue was up 44.6% on a year-over-year basis. During the same quarter last year, the company earned $0.80 earnings per share. Equities analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, June 4th. Shareholders of record on Friday, May 7th will be paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 3.90%. The ex-dividend date of this dividend is Thursday, May 6th. Pfizer’s dividend payout ratio (DPR) is currently 52.88%.

In other Pfizer news, SVP Jennifer B. Damico sold 2,500 shares of Pfizer stock in a transaction dated Wednesday, May 5th. The stock was sold at an average price of $40.82, for a total transaction of $102,050.00. Following the completion of the sale, the senior vice president now owns 13,748 shares of the company’s stock, valued at $561,193.36. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.08% of the company’s stock.

PFE has been the subject of a number of recent research reports. Barclays raised their target price on Pfizer from $37.00 to $40.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 5th. JPMorgan Chase & Co. raised their target price on Pfizer from $36.00 to $40.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 5th. Berenberg Bank reissued a “neutral” rating and issued a $38.00 target price on shares of Pfizer in a research report on Tuesday, March 23rd. DZ Bank reissued a “buy” rating and issued a $41.00 target price on shares of Pfizer in a research report on Wednesday, February 3rd. Finally, Morgan Stanley lifted their price target on Pfizer from $38.00 to $42.00 and gave the company an “equal weight” rating in a research report on Monday, May 10th. Twelve analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $39.74.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.

Read More: What are catch-up contributions?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.